Side-by-side · Research reference
CardiogenvsCerebrolysin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED5/46 cited
BPhase 3HUMAN-REVIEWED11/65 cited
Cardiogen
Bioregulator · Cardiac
CardiacTissue target
Gene regulationMechanism
AnimalEvidence level
SQ · Variable protocols
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
01Mechanism of Action
Parameter
Cardiogen
Cerebrolysin
Primary target
Cardiovascular cell gene expressionKhavinson 2022
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
Pathway
Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
Downstream effect
Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Feedback intact?
Presumed — peptide bioregulators act via gene regulation, not receptor agonism
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
Origin
Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Antibody development
—
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
02Dosage Protocols
Parameter
Cardiogen
Cerebrolysin
Standard dose
Variable — typically 10–20 mg per course
No standardised human protocol; animal-derived dosing.
—
Frequency
Intermittent courses — 10–20 days, repeated periodically
Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.
—
Evidence basis
Animal models / mechanistic studies
No Phase 1+ human trials in PubMed.
Phase 3 RCT + observational
Route
Subcutaneous injection
—
Duration
10–20 day courses, repeated 2–4× per year
Russian geriatric protocols; unclear extrapolation to general populations.
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
Standard dose (stroke)
—
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
Lower dose (dementia)
—
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
Timing (stroke)
—
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
Adjunct to thrombectomy
—
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
Administration route
—
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
04Side Effects & Safety
Parameter
Cardiogen
Cerebrolysin
Injection site reactions
Mild erythema, induration (presumed)
—
Systemic adverse events
No documented serious AEs in available literature
Very limited safety data; no rigorous pharmacovigilance.
—
Immunogenicity
Unknown — no antibody development studies published
—
Long-term safety
Unknown — no extended human trials indexed in PubMed
—
Injection site reaction
—
Mild pain, erythema (IM route)
Infusion reaction
—
Rare: flushing, transient hypotension during rapid IV
Agitation / Restlessness
—
Reported in <5% of patients; typically mild, self-limited
Serious adverse events
—
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
Hemorrhagic transformation
—
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
Mortality
—
No increase; meta-analysis RR 0.89 (0.68-1.18)
Allergic reaction
—
Rare; porcine origin theoretically immunogenic but clinically insignificant
Seizure risk
—
Not elevated; safe in epilepsy populations
Absolute Contraindications
Cardiogen
- ·Active malignancy (theoretical peptide growth factor concern)
- ·Hypersensitivity to peptide components
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Relative Contraindications
Cardiogen
- ·Acute cardiac events (no safety data in acute MI, unstable angina)
- ·Pregnancy / lactation (no reproductive toxicity data)
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
05Administration Protocol
Parameter
Cardiogen
Cerebrolysin
1. Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
3. Timing
Variable — often evening injection. No established circadian preference.
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
4. Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
5. Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
6. Co-administration
—
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
06Stack Synergy
Cardiogen
+ Thymalin
ModerateKhavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.
- Cardiogen
- 10–20 mg SQ · 10–20 day course
- Thymalin
- 10–30 mg IM · concurrent or sequential courses
- Frequency
- 2–4 courses per year
- Primary benefit
- Multi-system aging mitigation, cardiovascular and immune homeostasis
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery